In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 4_Supplement ( 2022-02-15), p. P4-06-04-P4-06-04
Abstract:
BACKGROUND: The residual cancer burden (RCB) is calculated utilizing these variables: tumor bed size, tumor/tumor bed ratio, percentage of DCIS, number of positive lymph nodes (LN) and the size of the largest LN. The aim of the study is to investigate if other variables related to the LNs correlate with the outcomes. METHODS: We conducted pathologic review of 129 patients who had triple negative breast cancer (TNBC) diagnosed between 2002 and 2006. The following variables were calculated, Finv: primary tumor/tumor bed ratio; dmet: diameter of largest involved LN; dprim= √d1d2 (d1 and d2 dimensions of the primary tumor bed); RCBprim = finv dprim ; RCBmet = 4 (1- 0.75LN) dmet; and RCB = 1.4 (finvdprim)0.17 + [4(1- 0.75 LN) dmet ]0.17. We calculated the LN tumor/tumor bed ratio (fLN), the number of resected LNs, and the number of LNs with therapy effect (with or without metastases). Clinical staging was abstracted from the medical records. Clinicopathologic variables were correlated with the recurrence free survival (RFS) and overall survival (OS). RESULTS: Most of the patients were treated with anthracycline based chemotherapy (CT) (90.7%). The median and range of follow up was 108.2 (15.0, 225.1) months. Pathology complete response (pCR) was achieved in 34.1% of the patients and correlated with age (p= 0.042) and clinical stage (p=0.004). pCR had better survival after 5-years (p & lt;0.001) and 10 years (p=0.001) follow up. In the univariate analysis the following variables were statistically significant correlating with RFS and OS including clinical stage, RCB, and fLN. These variables were statistically significant in the multivariate analysis for RFS including clinical stage with hazard ratio (HR) 0.37 (0.15, 0.89) (p=0.026) and fLN HR 1.01 (1.00, 1.02) (p=0.006); and for OS with HR 0.35 (0.14, 0.85) (p=0.02) and 1.01 (1.00, 1.02) (p=0.01), respectively. CONCLUSIONS: Adding LN tumor/tumor bed ratio (fLN) to the existing formula may improve the predictability power of the RCB index. Citation Format: Shipra Gandhi, Kristopher Attwood, Wenyan Ji, Saif Aljabab, Thaer Khoury. The role of axillary lymph node status in residual cancer burden calculation of triple negative breast cancer post-neoadjuvant cytotoxic chemotherapy [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-06-04.
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.SABCS21-P4-06-04
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2022
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
